183 related articles for article (PubMed ID: 31164454)
1. Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis.
Rochefort P; Lardy-Cleaud A; Sarabi M; Desseigne F; Cattey-Javouhey A; de la Fouchardière C
Oncologist; 2019 Dec; 24(12):1543-1548. PubMed ID: 31164454
[TBL] [Abstract][Full Text] [Related]
2. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
[TBL] [Abstract][Full Text] [Related]
4. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma.
Yu KH; Ozer M; Cockrum P; Surinach A; Wang S; Chu BC
Cancer Med; 2021 Dec; 10(24):8934-8943. PubMed ID: 34811961
[TBL] [Abstract][Full Text] [Related]
5. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia.
Body A; Wong R; Shapiro J; Jalali A; McLachlan SA; Ananda S; Lipton L; Cooray P; Gibbs P; Lee B; Lee M
Intern Med J; 2022 Jan; 52(1):49-56. PubMed ID: 33040452
[TBL] [Abstract][Full Text] [Related]
6. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
7. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
8. The evolution of clinical outcomes in metastatic pancreatic adenocarcinoma: a 10-year experience at a tertiary referral center.
Ellithi M; Abdallah M; Fischer M; Ailts I; Fanta J; Waligoske K; Bell M; Nelson ME; Bleeker J
Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):479-486. PubMed ID: 35400291
[TBL] [Abstract][Full Text] [Related]
9. Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma.
Kim HW; Lee JC; Paik KH; Lee YS; Hwang JH; Kim J
Medicine (Baltimore); 2015 Jun; 94(25):e1012. PubMed ID: 26107667
[TBL] [Abstract][Full Text] [Related]
10. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?
Frigerio I; Regi P; Giardino A; Scopelliti F; Girelli R; Bassi C; Gobbo S; Martini PT; Capelli P; D'Onofrio M; Malleo G; Maggino L; Viviani E; Butturini G
Ann Surg Oncol; 2017 Aug; 24(8):2397-2403. PubMed ID: 28516291
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis by site of primary tumor of patients with unresectable locally-advanced or metastatic pancreatic adenocarcinoma receiving chemotherapy.
Colloca GA; Venturino A; Guarneri D
Clin Exp Metastasis; 2019 Dec; 36(6):519-525. PubMed ID: 31578654
[TBL] [Abstract][Full Text] [Related]
12. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.
Piciucchi M; Stigliano S; Archibugi L; Zerboni G; Signoretti M; Barucca V; Valente R; Fave GD; Capurso G
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353661
[TBL] [Abstract][Full Text] [Related]
13. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
14. A Competing-Risks Nomogram in Patients with Metastatic Pancreatic Duct Adenocarcinoma.
Lu Y; Zhou Y; Cao Y; Shi Z; Meng Q
Med Sci Monit; 2019 May; 25():3683-3691. PubMed ID: 31102397
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
[TBL] [Abstract][Full Text] [Related]
16. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
17. Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma.
Varzaru B; Iacob RA; Croitoru AE; Iacob SM; Radu CE; Dumitrescu SM; Gheorghe C
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444612
[TBL] [Abstract][Full Text] [Related]
18. Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States.
Paluri R; Laursen A; Gaeta J; Wang S; Surinach A; Cockrum P
Oncologist; 2022 Jun; 27(6):e518-e523. PubMed ID: 35285490
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
